Meningococcal Serogroup A, C, W135 and Y Conjugated Vaccine: A Cost-Effectiveness Analysis in the Netherlands

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Hepkema, Hiltsje ^a   Pouwels, Koen B ^a   van der Ende, Arie ^b   Westra, Tjalke A ^a,c   Postma, Maarten J ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c GLAXOSMITHKLINE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

MENINGOCOCCUS VACCINE;

ADOLESCENT; ANAPHYLAXIS; ARTICLE; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; FEMALE; FOLLOW UP; HERD IMMUNITY; HUMAN; IMMUNIZATION; MAJOR CLINICAL STUDY; MALE; MENINGOCOCCOSIS; MORBIDITY; NETHERLANDS; NEWBORN; PRESCHOOL CHILD; PREVENTIVE HEALTH SERVICE; QUALITY ADJUSTED LIFE YEAR; SCHOOL CHILD; UNSPECIFIED SIDE EFFECT;

CHILD; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; HUMANS; IMMUNITY, HERD; IMMUNIZATION, SECONDARY; INFANT; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL VACCINES; MODELS, ECONOMIC; NEISSERIA MENINGITIDIS; NETHERLANDS; VACCINATION; VACCINES, CONJUGATE;

EID: 84878577043     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0065036     Document Type: Article

References (55)

1. World Health Organization (2011) Meningococcal vaccines: WHO position paper, November 2011. Wkly Epidemiol Rec 86: 521-539.
2. World Health Organization, SAGE Working Group (2011) Background paper on meningococcal vaccines. Available: http://www.who.int/immunization/sage/1_mening_background_document_v5_3__apr_2011.pdf. Accessed 22 June 2012.
3. Oostenbrink R, Maas M, Moons KG, Moll HA, (2002) Sequelae after bacterial meningitis in childhood. Scand J Infect Dis 34: 379-382.
4. Scholten RJ, Bijlmer HA, Valkenburg HA, Dankert J, (1994) Patient and strain characteristics in relation to the outcome of meningococcal disease: A multivariate analysis. Epidemiol Infect 112: 115-124.
5. De Greeff SC, de Melker HE, Spanjaard L, Schouls LM, van Derende A, (2006) Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in the Netherlands. Pediatr Infect Dis J 25: 79-80.
6. Maiden MC, Ibarz-Pavon AB, Urwin R, Gray SJ, Andrews NJ, et al. (2008) Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis 197: 737-743.
7. Trotter CL, Maiden MC, (2009) Meningococcal vaccines and herd immunity: Lessons learned from serogroup C conjugate vaccination programs. Expert Rev Vaccines 8: 851-861.
8. De Voer RM (2010) Meningococcal C specific immune responses: Immunity in an era of immunization with vaccine. Utrecht: Utrecht University.
9. Christensen H, May M, Bowen L, Hickman M, Trotter CL, (2010) Meningococcal carriage by age: A systematic review and meta-analysis. Lancet Infect Dis 10: 853-861.
10. De Voer RM, Mollema L, Schepp RM, de Greeff SC, van Gageldonk PG, et al. (2010) Immunity against Neisseria meningitides serogroup C in the Dutch population before and after introduction of the meningococcal C conjugate vaccine. PloS One 5: e12144.
11. Ishola DA Jr, Borrow R, Findlow H, Findlow J, Trotter C, et al. (2012) Prevalence of serum bactericidal antibody to serogroup C Neisseria meningitides in England a decade after vaccine introduction. Clin Vaccine Immunol 19: 1126-1130.
12. Kaaijk P, van der Ende A, Berbers G, van den Dobbelsteen GP, Rots NY, (2012) Is a single dose of meningococcal serogroup C conjugate vaccine sufficient for protection? Experience from the Netherlands. BMC Infect Dis 12: 35-2334-12-35.
13. Ministry of Health Austria (2012) Immunization schedule Austria. Available: http://www.bmg.gv.at/cms/home/attachments/7/3/0/CH1081/CMS1286449898381/impfplan_2012_final,_1.2.2012.pdf. Accessed 2012 Jul 19.
14. World Health Organization (2012) Immunization schedule Switzerland. Available: http://apps.who.int/immunization_monitoring/en/globalsummary/ScheduleResult.cfm. Accessed 2012 Jul 19.
15. Netherlands Reference Laboratory for Bacterial Meningitis. Bacterial meningitis in the Netherlands. Annual reports 2007-2011. Amsterdam: University of Amsterdam, the Netherlands.
16. European Medicines Agency (2012) EPAR-summary for the public: Nimenrex (EMA/CHMP/136315/2012). Available: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/002226/WC500127665.pdf. Accessed 2012 Dec 14.
17. Hakkaart-van Roijen L, Tan SS, Bouwmans CAM (2010) Guidelines for costing research, methods and standardized prices for economic evaluations in health care. Diemen: Health Care Insurance Board.
18. Statistics Netherlands. Available: http://statline.cbs.nl. Accessed 2012 Nov 15.
19. European Union invasive bacterial infections surveillance network (2001) Invasive Neisseria meningitides in Europe -2001. Available: http://www.hpa-bioinformatics.org.uk/euibis/documents/2001_meningo.pdf. Accessed 2012 Dec 14.
20. Welte R, van den Dobbelsteen G, Bos JM, de Melker H, van Alphen L, et al. (2004) Economic evaluation of meningococcal serogroup C conjugate vaccination programmes in the Netherlands and its impact on decision-making. Vaccine 23: 470-479.
21. Stouthard MEA, Essink-Bot ML, Bonsel GJ, Barendregt JJ, Kramers PGN, et al. (1997) Disability weights for disease in the Netherlands. Rotterdam: Department of Public Health, Erasmus University, the Netherlands.
22. Dutch Ministry of Education Culture and Science (2012) Key figures 2007-2011. Available: http://www.government.nl/documents-and-publications/reports/2012/07/24/key-figures-2007-2011.html. Accessed 2012 May 16.
23. College of Health Insurances. Pharmaceutical price meningococcal serogroup ACWY vaccine (Nimenrix®). Available: http://www.medicijnkosten.nl/. Accessed 2012 Jul 26.
24. College of Health Insurances. Pharmaceutical price meningococcal serogroup C vaccine (Neisvac-C®). Available: http://www.medicijnkosten.nl/. Accessed 2012 Jul 26.
25. Knuf M, Kieninger-Baum D, Habermehl P, Muttonen P, Maurer H, et al. (2010) A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children. Vaccine 28: 744-753.
26. Knuf M, Pantazi-Chatzikonstantinou A, Pfletschinger U, Tichmann-Schumann I, Maurer H,et al. An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered with Infanrix hexa is immunogenic, with an acceptable safety profile in 12-23-month-old children. Vaccine 29: 4264-4273.
27. Vesikari T, Karvonen A, Bianco V, van der Wielen M, Miller J, (2011) Tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when co-administered with measles-mumps-rubella-varicella vaccine during the second year of life: An open, randomized controlled trial. Vaccine 29: 4274-4284.
28. Vesikari T, Forsten A, Boutriau D, Bianco V, van der Wielen M, et al. (2012) Randomized trial to assess the immunogenicity, safety and antibody persistence up to three years after a single dose of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers. Hum Vaccin Immunother 8. doi: http://dx.doi.org/10.4161/hv.22166.
29. Campbell H, Borrow R, Salisbury D, Miller E, (2009) Meningococcal C conjugate vaccine: The experience in England and Wales. Vaccine 27Suppl 2: B20-9.
30. Campbell H, Andrews N, Borrow R, Trotter C, Miller E, (2010) Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: Effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity. Clin Vaccine Immunol 17: 840-847.
31. Rozenbaum MH, Sanders EA, van Hoek AJ, Jansen AG, van der Ende A, et al. (2010) Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines. BMJ 304: c2509.
32. De Wals P, Trottier P, Pépin J, (2006) Relative efficacy of different immunization schedules for the prevention of serogroup C meningococcal disease: a model-based evaluation. Vaccine 24: 3500-3504.
33. Harrison LH, Trotter CL, Ramsay ME, (2009) Global epidemiology of meningococcal disease. Vaccine 27Suppl 2: B51-63.
34. Halperin SA, Bettinger JA, Greenwood B, Harrison LH, Jelfs J, et al. (2012) The chancing and dynamic epidemiology of meningococcal disease. Vaccine 30 Suppl2: B26-36.
35. Kauf TL, (2010) Methodological concerns with economic evaluations of meningococcal vaccines. Pharmacoeconomics 28: 449-461.
36. Drummond M, Chevat C, Lothgren M, (2007) Do we fully understand the economic value of vaccines? Vaccine 25: 5945-5957.
37. Larrauri A, Cano R, Garcia M, Mateo S, (2005) Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain. Vaccine 23: 4097-4100.
38. Chen RT, Orenstein WA, (1996) Epidemiologic methods in immunization programs. Epidemiol Rev 18: 99-117.
39. Spanjaard L, Bol P, de Marie S, Zanen HC, (1987) Association of meningococcal serogroups with the course of disease in the Netherlands, 1959-83. Bull World Health Organ 65: 861-868.
40. Trotter CL, Ramsay ME, Gray S, Fox A, Kaczmarski E, (2006) No evidence for capsule replacement following mass immunisation with meningococcal serogroup C conjugate vaccines in England and Wales. Lancet Infect Dis 6: 616-617.
41. European Medicines Agency (2013) EPAR-summary for the public: Bexsero (EMA/755874/2012). Available: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002333/human_med_001614.jsp&mid=WC0b01ac058001d124. Accessed 2013 Mar 5.
42. Pouwels KB, Hak E, van der Ende A, Christensen H, van den Dobbelsteen GPJM, et al. (2013) Cost-effectiveness of vaccination against meningococcal B among Dutch infants: crucial impact of changes in incidence. Hum Vaccin Immunother 9. doi: http://dx.doi.org/10.4161/hv.23888.
43. Vesikari T, Esposito S, Prymula R, Ypma E, Kohl I, et al. (2013) Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomized trials. Lancet 381: 825-835.
44. Gill CJ (2013) Novel assessment of a novel meningitis B vaccine. Lancet Infect Dis. doi: http://dx.doi.org/10.1016/S1473-3099(13)70037-9.
45. Shepard CW, Ortega-Sanchez IR, Scott RD 2nd, Rosenstein NE, ABCs Team (2005) Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States. Pediatrics 115: 1220-1232.
46. Ortega-Sanchez IR, Meltzer MI, Shepard C, Zell E, Messonnier ML, et al. (2008) Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States. CID 46: 1-13.
47. De Wals P, Coudeville L, Trottier P, Chevat C, Erickson LJ, et al. (2007) Vaccinating adolescents against meningococcal disease in Canada: A cost-effectiveness analysis. Vaccine 25: 5433-5440.
48. Medicines Control Agency (2000) Safety of meningococcal group C conjugate vaccines. Current Problems in Pharmacovigilance 26: 14.
49. Van Lier EA, Oomen PJ, Giesbers H, Drijfhout IH, de Hoogh PAAM, et al. (2012) Immunization coverage National Immunization Programme in the Netherlands: Year of report 2012. Report no. 201001001, National Institute of Health and the Environment, Bilthoven, the Netherlands.
50. Neppelenbroek SE, de Vries M, Greeff SC, Timen A (2002) 'da's goed gedaan? Woordverslag van de landelijke vaccinatiecampagne meningokokken C. ISBN 90-72779-38-X. 2003. GGD Nederland.
51. De Greeff SC, de Melker HE, Schouls LM, Spanjaard L, van Deuren M, (2008) Pre-admission clinical course of meningococcal disease and opportunities for the earlier start of appropriate intervention: a prospective epidemiological study on 752 patients in the Netherlands, 2003-2005. Eur J Clin Microbriol Infect Dis 27: 985-992.
52. Van Deuren M, Brandtzaeg P, van der Meer JW, (2000) Update on meningococcal disease with emphasis on pathogenesis and clinical management. Clin Microbiol Rev 13: 144-166.
53. Dutch Healthcare Authority. Medical specialized treatment and its tariffs 2011. Available: http://www.nza.nl/137706/145406/BR-CU-2015_bijlage_2_med.spec.behandelingen-en-tarieven_2011.xls. Accessed 2012 May 28.
54. Dutch Association of Hospitals. Number of general hospitals to bed numbers. Available: http://www.nvz-ziekenhuizen.nl/feiten_en_cijfers/FAQ#beddenaantal. Accessed 2012 May 28.
55. Kind P, Hardman G, Macran S. (1999) UK population norms for EQ-5D. Discussion paper 172. The University of York Centre for Health Economics. Available: http://www.york.ac.uk/inst/che/pdf/DP172.pdf. Accessed 2012 Jun 1.